Jeff T Hutchins
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$9.2MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $9.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 2, 2025 | NIH | SBIR Phase II Development of IN-003PI as passive immunization against human metapneumovirus infection | $1.0M | Inhalon Biopharma, Inc. |
| Jul 30, 2025 | NIH | SBIR Phase II IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A | $1.0M | Inhalon Biopharma, Inc. |
| May 8, 2025 | NIH | SBIR Phase II IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection | $1.0M | Inhalon Biopharma, Inc. |
| Apr 9, 2025 | NIH | SBIR Phase II SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections | $1.0M | Inhalon Biopharma, Inc. |
| Jun 21, 2024 | NIH | SBIR Phase II Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV | $1.0M | Inhalon Biopharma, Inc. |
| May 15, 2024 | NIH | SBIR Phase II IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection | $1.0M | Inhalon Biopharma, Inc. |
| Mar 1, 2024 | NIH | SBIR Phase II SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections | $1.0M | Inhalon Biopharma, Inc. |
| Jun 27, 2023 | NIH | SBIR Phase II IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus | $1.0M | Inhalon Biopharma, Inc. |
| Jul 12, 2022 | NIH | SBIR Phase II IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus | $1.0M | Inhalon Biopharma, Inc. |
Peer ranks
Federal funding#83
Awards as PI#151
Patents#273
Companies
- Inhalon Biopharma, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.